To the best of our knowledge, this study is the first report demonstrating that bone responsiveness to PTH is significantly negatively associated with the intravenous administration of CaSR agonist and/or VDRA in patients undergoing chronic HD. The gene discussed is CASR; the disease is Huntington disease.